Waters Corp Presents Strategic Rationale and Synergies for BD Biosciences & Dx Acquisition at J.P. Morgan Conference
WAT sits 43% above its 52-week low of $275.05.
Summary
Waters Corporation presented an investor update at the J.P. Morgan Healthcare Conference, detailing the strategic rationale, significant cost and revenue synergies, and an industry-leading financial outlook for its proposed acquisition of BD Biosciences & Diagnostic Solutions.
Key Events · M&A and Partnerships · WAT
-
Investor Presentation at J.P. Morgan Conference
Waters Corporation delivered an investor presentation at the J.P. Morgan Healthcare Conference on January 12, 2026, including high-level commentary on business performance.
-
Strategic Rationale for BD Biosciences & Dx Acquisition
The presentation detailed the strategic rationale for acquiring BD Biosciences & Diagnostic Solutions, highlighting its role in accelerating high-growth adjacencies and leveraging commercial scale.
-
Significant Synergy Targets
Waters projected $200 million in cost synergies and $290 million in revenue synergies ($145 million in Adjusted EBITDA) from the acquisition.
-
Doubling Total Addressable Market
The transaction is expected to double Waters' total addressable market (TAM) to $40 billion in attractive, growth-accretive markets.
Analysis · WAT · Industrial Applications And Services
Waters Corporation used its presentation at the J.P. Morgan Healthcare Conference to provide a comprehensive overview of its proposed acquisition of BD Biosciences & Diagnostic Solutions. The company emphasized the strategic benefits, including doubling its total addressable market to $40 billion and accelerating growth in high-growth adjacencies. Management outlined substantial synergy targets, projecting $200 million in cost synergies and $290 million in revenue synergies, which are expected to significantly enhance the combined entity's financial performance. The presentation also provided an updated financial outlook, positioning the combined company for industry-leading revenue growth, EBIT margin expansion, and EPS growth. This detailed strategic and financial justification for a major transaction is highly material for investors.
At the time of this filing, WAT was trading at $393.68 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $23.4B. The 52-week trading range was $275.05 to $423.56. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.